Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

Vortex, as per Glickman comparison between Restasis and VOS, VOS has more drug contents per eyedrop than Restasis and will take that as a factor in in the p2b or p3 designs. VOS could end up better in tolerability than Restasis after the next trials. If you are a doctor, how can u ignore the drug that delivers more than twice the efficacy with the same SOC tolerability. If VOS is not bought before the next trials commence, I would expect VOS to become the SOC in this Dry Eye Syndrome indication.